SI2547679T1 - Derivati 2,3 dihidro-1H-inden-1-il-2,7-diazaspiro(3.6)nonana in njihova uporaba kot antagonisti ali inverzni agonisti grelinskega receptorja - Google Patents
Derivati 2,3 dihidro-1H-inden-1-il-2,7-diazaspiro(3.6)nonana in njihova uporaba kot antagonisti ali inverzni agonisti grelinskega receptorjaInfo
- Publication number
- SI2547679T1 SI2547679T1 SI201130664T SI201130664T SI2547679T1 SI 2547679 T1 SI2547679 T1 SI 2547679T1 SI 201130664 T SI201130664 T SI 201130664T SI 201130664 T SI201130664 T SI 201130664T SI 2547679 T1 SI2547679 T1 SI 2547679T1
- Authority
- SI
- Slovenia
- Prior art keywords
- diazaspiro
- inden
- antagonists
- dihydro
- inverse agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31552210P | 2010-03-19 | 2010-03-19 | |
US201161444401P | 2011-02-18 | 2011-02-18 | |
PCT/IB2011/051035 WO2011114271A1 (en) | 2010-03-19 | 2011-03-11 | 2,3 dihydro-1h-inden-1-yl- 2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor |
EP11713083.1A EP2547679B1 (en) | 2010-03-19 | 2011-03-11 | 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2547679T1 true SI2547679T1 (sl) | 2015-12-31 |
Family
ID=44647714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201130664T SI2547679T1 (sl) | 2010-03-19 | 2011-03-11 | Derivati 2,3 dihidro-1H-inden-1-il-2,7-diazaspiro(3.6)nonana in njihova uporaba kot antagonisti ali inverzni agonisti grelinskega receptorja |
Country Status (26)
Country | Link |
---|---|
US (2) | US8609680B2 (sl) |
EP (1) | EP2547679B1 (sl) |
JP (1) | JP5496409B2 (sl) |
KR (1) | KR101455917B1 (sl) |
CN (1) | CN102939290B (sl) |
AR (1) | AR080688A1 (sl) |
AU (1) | AU2011228699B2 (sl) |
BR (1) | BR112012023664B1 (sl) |
CA (1) | CA2792234C (sl) |
CY (1) | CY1118721T1 (sl) |
DK (1) | DK2547679T3 (sl) |
ES (1) | ES2557895T3 (sl) |
HK (1) | HK1182094A1 (sl) |
HR (1) | HRP20151232T1 (sl) |
HU (1) | HUE025774T2 (sl) |
IL (1) | IL221952A (sl) |
ME (1) | ME02330B (sl) |
MX (1) | MX2012010772A (sl) |
PL (1) | PL2547679T3 (sl) |
PT (1) | PT2547679E (sl) |
RS (1) | RS54383B1 (sl) |
RU (1) | RU2524341C2 (sl) |
SG (1) | SG183812A1 (sl) |
SI (1) | SI2547679T1 (sl) |
TW (1) | TWI410423B (sl) |
WO (1) | WO2011114271A1 (sl) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014029577A2 (pt) * | 2012-06-04 | 2017-06-27 | Pfizer | uso de agonistas ou antagonistas inversos do receptor de grelina para tratamento de transtornos do sono |
NZ702334A (en) * | 2012-06-13 | 2016-11-25 | Hoffmann La Roche | New diazaspirocycloalkane and azaspirocycloalkane |
SG11201500572YA (en) | 2012-09-25 | 2015-02-27 | Hoffmann La Roche | New bicyclic derivatives |
AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
MA38982A1 (fr) | 2013-11-26 | 2017-09-29 | Hoffmann La Roche | Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl |
AU2015233642B2 (en) * | 2014-03-17 | 2017-08-03 | Remynd Nv | 2,7-diazaspiro[3.5]nonane compounds |
EP3122751B1 (en) | 2014-03-26 | 2019-10-30 | F.Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
UA118582C2 (uk) | 2014-03-26 | 2019-02-11 | Ф. Хоффманн-Ля Рош Аг | Біциклічні сполуки як інгібітори продукції аутотаксину (atx) і лізофосфатидилової кислоти (lpa) |
CN104610143A (zh) * | 2015-02-12 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途 |
MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
MX2018000511A (es) | 2015-09-04 | 2018-04-24 | Hoffmann La Roche | Derivados de fenoximetilo. |
KR20180054634A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물 |
AU2016328365B2 (en) | 2015-09-24 | 2020-04-23 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
JP6846414B2 (ja) | 2015-09-24 | 2021-03-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Atx阻害剤としての二環式化合物 |
RU2018112230A (ru) | 2015-09-24 | 2019-10-30 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов atx |
KR20180096406A (ko) | 2017-02-21 | 2018-08-29 | 엘지전자 주식회사 | 냉장고 |
WO2018167113A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
CA3053329A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | Heterocyclic compounds useful as dual atx/ca inhibitors |
IL272258B (en) * | 2017-07-28 | 2022-08-01 | Chemocentryx Inc | Immunomodulator compounds |
CN108588215A (zh) * | 2018-05-03 | 2018-09-28 | 成都中创清科医学检验所有限公司 | 一种用于检测家族性高胆固醇血症易感性相关的snp位点的引物及其检测方法 |
CN109970631A (zh) * | 2019-03-26 | 2019-07-05 | 上海吉奉生物科技有限公司 | 一种5-碘-2-吡啶乙酸的合成方法 |
CN110256349B (zh) * | 2019-04-23 | 2020-09-08 | 苏州大学 | 多取代吡唑及其制备方法 |
CN110172062B (zh) * | 2019-06-21 | 2022-01-07 | 南京药石科技股份有限公司 | 一种单氟代螺环化合物的合成方法及其中间体 |
WO2022111624A1 (zh) | 2020-11-27 | 2022-06-02 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
KR20220001745U (ko) | 2021-01-06 | 2022-07-13 | 성보라 | 자동차시트 후면 보호용 보조커버 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
RS63203A (en) | 2001-02-28 | 2006-12-15 | Merck & Co.Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
ES2272776T3 (es) | 2001-09-21 | 2007-05-01 | Schering Corporation | Tratamiento de xantomas con derivados de azetidinona como inhibidores de la absorcion de esterol. |
IL163659A0 (en) | 2002-02-27 | 2005-12-18 | Pfizer Prod Inc | Acc inhibitors |
SE0302811D0 (sv) * | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
ATE437870T1 (de) | 2004-05-12 | 2009-08-15 | Pfizer Prod Inc | Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren |
AU2005247693A1 (en) | 2004-05-25 | 2005-12-08 | Pfizer Products Inc. | Tetraazabenzo[E]azulene derivatives and analogs thereof |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
GB0514018D0 (en) * | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
US20070161578A1 (en) | 2005-12-21 | 2007-07-12 | Hwa Joyce J | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist |
WO2007122482A1 (en) | 2006-04-20 | 2007-11-01 | Pfizer Products Inc. | Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
MX2009002918A (es) * | 2006-09-15 | 2009-03-31 | Schering Corp | Derivados azetidinona y sus metodos de uso. |
JP2010503675A (ja) * | 2006-09-15 | 2010-02-04 | シェーリング コーポレイション | 疼痛、糖尿病および脂質代謝の障害の治療に有用なスピロ縮合アゼチジン誘導体 |
JP2010511035A (ja) | 2006-11-29 | 2010-04-08 | ファイザー・プロダクツ・インク | スピロケトンアセチルCoAカルボキシラーゼ阻害剤 |
US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
CA2724603A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
ES2545231T3 (es) | 2008-05-28 | 2015-09-09 | Pfizer Inc. | Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa |
US20110071129A1 (en) * | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
JP2011529483A (ja) | 2008-07-29 | 2011-12-08 | ファイザー・インク | フッ素化ヘテロアリール |
WO2010023594A1 (en) | 2008-08-28 | 2010-03-04 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
PL2406253T3 (pl) | 2009-03-11 | 2013-10-31 | Pfizer | Pochodne benzofuranylu jako inhibitory glukokinazy |
WO2010103438A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
CA2754523A1 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
TW201038572A (en) * | 2009-03-25 | 2010-11-01 | Gruenenthal Gmbh | Substituted spiro-amide compounds |
JP2012526096A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Gpr119調節因子 |
JP2012526097A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Gpr119調節因子 |
SG175995A1 (en) | 2009-06-05 | 2011-12-29 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
WO2010141817A1 (en) * | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
-
2011
- 2011-03-11 HU HUE11713083A patent/HUE025774T2/en unknown
- 2011-03-11 BR BR112012023664A patent/BR112012023664B1/pt not_active IP Right Cessation
- 2011-03-11 SI SI201130664T patent/SI2547679T1/sl unknown
- 2011-03-11 AU AU2011228699A patent/AU2011228699B2/en not_active Ceased
- 2011-03-11 PT PT117130831T patent/PT2547679E/pt unknown
- 2011-03-11 DK DK11713083.1T patent/DK2547679T3/en active
- 2011-03-11 EP EP11713083.1A patent/EP2547679B1/en active Active
- 2011-03-11 SG SG2012062667A patent/SG183812A1/en unknown
- 2011-03-11 CA CA2792234A patent/CA2792234C/en not_active Expired - Fee Related
- 2011-03-11 MX MX2012010772A patent/MX2012010772A/es active IP Right Grant
- 2011-03-11 PL PL11713083T patent/PL2547679T3/pl unknown
- 2011-03-11 WO PCT/IB2011/051035 patent/WO2011114271A1/en active Application Filing
- 2011-03-11 KR KR1020127027230A patent/KR101455917B1/ko active IP Right Grant
- 2011-03-11 RS RS20150808A patent/RS54383B1/en unknown
- 2011-03-11 RU RU2012137489/04A patent/RU2524341C2/ru not_active IP Right Cessation
- 2011-03-11 JP JP2013500620A patent/JP5496409B2/ja not_active Expired - Fee Related
- 2011-03-11 ME MEP-2015-189A patent/ME02330B/me unknown
- 2011-03-11 CN CN201180014627.7A patent/CN102939290B/zh not_active Expired - Fee Related
- 2011-03-11 ES ES11713083.1T patent/ES2557895T3/es active Active
- 2011-03-16 TW TW100109022A patent/TWI410423B/zh not_active IP Right Cessation
- 2011-03-16 US US13/049,225 patent/US8609680B2/en active Active
- 2011-03-18 AR ARP110100888A patent/AR080688A1/es not_active Application Discontinuation
-
2012
- 2012-09-13 IL IL221952A patent/IL221952A/en not_active IP Right Cessation
-
2013
- 2013-08-08 HK HK13109302.9A patent/HK1182094A1/zh not_active IP Right Cessation
- 2013-11-18 US US14/083,275 patent/US20140080756A1/en not_active Abandoned
-
2015
- 2015-11-16 HR HRP20151232TT patent/HRP20151232T1/hr unknown
- 2015-12-04 CY CY20151101105T patent/CY1118721T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2547679T1 (sl) | Derivati 2,3 dihidro-1H-inden-1-il-2,7-diazaspiro(3.6)nonana in njihova uporaba kot antagonisti ali inverzni agonisti grelinskega receptorja | |
ZA201105323B (en) | Agonists and antagonists of the sip5 receptor,and methods of uses thereof | |
HK1187606A1 (zh) | 取代的 -稠合含氮雜環化合物及其用途 | |
HK1188211A1 (zh) | 受體拮抗劑 | |
HK1170737A1 (zh) | 萘啶衍生物及其作為激酶抑制劑的用途 | |
AP2012006276A0 (en) | New CCR2 receptor antagonists and uses thereof. | |
ZA201207259B (en) | 4-aminopyrimidine derivatives and their as as adenosine 121 receptor antagonists | |
IL218938A0 (en) | Salts, solvates, and pharmaceutical compositions of macrocyclic ghrelin receptor agonists and methods of using the same | |
MY160665A (en) | Spiropiperidine compounds as orl-1 receptor antagonists | |
IL205608A0 (en) | Triazole -substituted arylamide derivatives and their use as p2x3 and/or p2x2/3purinergic receptor antagonists | |
AP2012006204A0 (en) | Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists. | |
PL2238110T3 (pl) | Pochodne 5,6-bisarylo-2-pirydyno-karboksamidu, ich wytwarzanie i ich zastosowanie terapeutyczne jako antagonistów receptora Urotensyny II | |
EP2552209A4 (en) | NOVEL IMIDAZOLONE SPIRO DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR USE THEREOF | |
EP2125724A4 (en) | NAPHTHALENE DERIVATIVES AND QUINOLINE SULFONYLUREA AS ANTAGONISTS OF THE EP4 RECEPTOR | |
IL225299A0 (en) | 7-Hydroxy-pyrazolo[1,5-a]pyrimidine compounds and their use as ccr2 receptor antagonists | |
IL200380A0 (en) | Mineralcorticoid receptor antagonists for the treatment of endometriosis | |
EP2563777A4 (en) | INVERSE AGONISTS AND NEUTRAL AGONISTS FOR THE TSH RECEPTOR | |
EP2531485A4 (en) | HIGHLY SELECTIVE 5-HT (2C) RECEPTOR AGONISTS HAVING ANTAGONIST ACTIVITY AT THE 5-HT (2B) RECEPTOR | |
AU2011345414A1 (en) | Substituted methyl amines, serotonin 5-HT6 receptor antagonists, methods for the production and use thereof | |
EP2657225A4 (en) | SUBSTITUTED METHYL AMINES, 5-HT6 SEROTONIN RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING | |
IL185640A0 (en) | Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists | |
HK1186176A1 (en) | Glycine derivatives and their use as muscarinic receptor antagonists | |
EP2351756A4 (en) | SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO [1,5-A] PYRIMIDINES, SEROTONIN-5-HT6 RECEPTOR ANTAGONISTS, AND METHOD FOR THEIR PREPARATION AND USE | |
IL211803A0 (en) | Quinazoline derivatives as nk3 receptor antagonists | |
IL235215A0 (en) | The l-malate salt of 7,2-diaza-spiro [4.5]7-dec yla, its derivatives and crystalline forms as ghrelin receptor agonists |